Abstract Number: 1782 • 2015 ACR/ARHP Annual Meeting
a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan
Background/Purpose: In Japan hydroxychloroquine (HCQ) is still unavailable due to the banning of chloroquine in 1974 following allegations that it caused severe retinopathy. Therefore, a…Abstract Number: 1783 • 2015 ACR/ARHP Annual Meeting
Dietary Fish Oil Supplementation Raises Serum Essential Fatty Acid Concentrations in Patients with Systemic Lupus Erythematosus and Correlates with Improvements in Inflammation and Pain
Background/Purpose: A comprehensive metabolomic screen comparing sera from patients with systemic lupus erythematosus (SLE) to healthy controls (HC) indicated a relative deficiency in omega-3 fatty…Abstract Number: 1784 • 2015 ACR/ARHP Annual Meeting
Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine
Background/Purpose: To explore the impact of SLE disease and belimumab given in addition to standard of care therapy on antibody response after vaccination with PCV13…Abstract Number: 1785 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Relative Factors of Infections in Southern Chinese Patients with Systemic Lupus Erythematosus
Background/Purpose: To determine the clinical characteristics and to identify relative factors of infection in patients with Systemic Lupus Erythematosus, to provide a data for making…Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…Abstract Number: 1787 • 2015 ACR/ARHP Annual Meeting
Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, compared to…Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…Abstract Number: 1789 • 2015 ACR/ARHP Annual Meeting
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: SLE is associated with a significantly increased risk of infection. Both disease activity and the medications required to control disease are contributory factors. Rituximab…Abstract Number: 1790 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Background/Purpose: To determine the efficacy of pneumococcal polysaccharide vaccine (PPV-23) in patients on mycophenolate mofetil (MMF) therapy and compare efficacy to other DMARDS.Methods: In…Abstract Number: 1791 • 2015 ACR/ARHP Annual Meeting
Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study
Background/Purpose: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently used as an adjuvant treatment in lupus nephritis (LN) patients for the…Abstract Number: 1792 • 2015 ACR/ARHP Annual Meeting
Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review
Background/Purpose: Premature coronary heart disease (CHD) represents a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE). Several studies have been conducted to…Abstract Number: 1793 • 2015 ACR/ARHP Annual Meeting
Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus
Background/Purpose: Elevated muscle enzymes in the course of systemic lupus erythematosus (SLE) usually represent active myositis or drug-related toxicity. Lipid-lowering agents and, less frequently, antimalarials…Abstract Number: 1794 • 2015 ACR/ARHP Annual Meeting
Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients
Background/Purpose: We have observed a decline in rates of cardiovascular events in systemic lupus erythamatosus (SLE) pateints in our clinic. In this work presented below,…Abstract Number: 1795 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Background/Purpose: Tacrolimus (Tac) is an immunosuppressive macrolide that blocks T cell activation by specifically inhibiting calcineurin. Some randomized controlled studies have shown that TAC is an…Abstract Number: 1796 • 2015 ACR/ARHP Annual Meeting
Progression of Atherosclerosis Might be Prevented By Decrease of Serum Resistin Level after Glucocorticoid Therapy in Patients with Systemic Autoimmune Disease
Background/Purpose: Development of atherosclerosis is accelerated in patients with systemic autoimmune diseases. However, underlying mechanisms of accelerated atherosclerosis remains unknown, and the impact of pharmacotherapies…
ACR Meeting Abstracts